Sex differences in stroke therapies.

Area of Science:

• Neurology
• Pharmacology
• Clinical Trials

Background:

• Stroke is a leading cause of death and disability, particularly impacting aged women.
• Existing stroke therapies often fail in clinical trials, possibly due to a lack of sex-specific considerations.
• Tissue plasminogen activator (tPA) is the sole FDA-approved stroke therapy, with observed sex-based differences in efficacy.

Purpose of the Study:

• To evaluate the impact of sex as a variable in stroke therapy research.
• To analyze existing data for sex-specific responses to stroke treatments.
• To advocate for sex-inclusive study designs in preclinical and clinical stroke research.

Main Methods:

• Reanalysis of data from tissue plasminogen activator (tPA) studies.
• Review of experimental evidence for novel stroke therapies including anti-inflammatory drugs, cell survival stimulators, and cell death inhibitors.
• Examination of ongoing clinical trials for stem cell therapy and cortical stimulation.

Main Results:

• Tissue plasminogen activator (tPA) demonstrates improved stroke outcomes in both sexes, with a more robust effect observed in females.
• Preclinical evidence supports investigating sex as a variable for various novel stroke therapies.
• Current clinical trials and preclinical studies often lack systematic reporting of sex-based differences.

Conclusions:

• Incorporating sex as a biological variable is crucial for developing effective stroke therapies.
• Future stroke research and clinical trials must include both sexes equally and analyze data for sex-specific differences.
• Systematic reporting of sex-based findings will enhance the development of stroke recovery treatments for all individuals.